Pulmonary vasoregulation by endothelin in conscious dogs after left lung transplantation

SHOUZABUROH DOI,1 NICHOLAS SMEDIRA,2 AND PAUL A. MURRAY1

1Center for Anesthesiology Research and 2Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195

Doi, Shouzaburoh, Nicholas Smedira, and Paul A. Murray. Pulmonary vasoregulation by endothelin in conscious dogs after left lung transplantation. J. Appl. Physiol. 88: 210–218, 2000.—We tested the hypothesis that regulation of the pulmonary circulation by endogenous endothelin (ET) during normoxia and hypoxia was altered in conscious dogs 1 mo after left lung autotransplantation (LLA). Sham-operated control and post-LLA dogs were chronically instrumented to measure the left pulmonary vascular pressure-flow (LP-Q˙) relationship. LP-Q˙ plots were generated on separate days during normoxia and hypoxia (arterial PO2 ~ 50 Torr) in the intact condition, after selective ETA-receptor inhibition (BQ-485), and after combined ETA,ETB-receptor inhibition (bosentan). Although LLA resulted in a chronic increase in pulmonary vascular resistance, the ET-receptor antagonists had no effect on the LP-Q˙ relationship during normoxia in either group. The magnitude of hypoxic pulmonary vasoconstriction (HPV) was flow dependent in both groups, and the HPV response was potentiated post-LLA compared with control. ETA-receptor inhibition attenuated the HPV response to the same extent in both groups. ETAB-receptor inhibition attenuated the HPV response to a greater extent than did ETAr-receptor inhibition alone, and this effect was greater post-LLA compared with control. Plasma ET-1 concentration only increased during hypoxia in the LLA group. These results indicate that ET does not regulate the baseline LP-Q˙ relationship in either group. Both ETAr and ETBr-receptor activation mediate a component of HPV in conscious dogs, and the vasoconstrictor influence of ETBr-receptor activation is enhanced post-LLA.

Pulmonary vascular pressure-flow relationship; endothelin-receptor antagonists; hypoxic pulmonary vasoconstriction

Endothelin (ET)-1 is a 21-amino acid peptide released from vascular endothelial cells (53). ET has a potent vasoconstrictor effect mediated by several receptor subtypes (ETAr and ETBr receptors) (43, 46, 49). ET is known to be increased in some forms of chronic pulmonary hypertension (2, 3, 8). ET has also been implicated as a mediator of acute hypoxic pulmonary vasoconstriction (HPV) (5, 33, 48).

Our laboratory has been systematically investigating chronic changes in pulmonary vascular regulation that occur after left lung autotransplantation (LLA). This experimental model allows us to perform experiments with animals in the conscious state, which eliminates the effects of anesthetics which are known to alter neural (4), humoral (32), and local (30) mechanisms of pulmonary vasoregulation. Experiments were performed ~4–5 wk after the surgical procedure; therefore, the effects of acute surgical trauma were minimized. Finally, the use of LP-Q plots avoids the problems inherent in the interpretation of single-point calculations of pulmonary vascular resistance (14) and allows us to distinguish between active and passive changes in the pulmonary circulation in response to the various interventions.

METHODS

All surgical procedures and experimental protocols were approved by the Institutional Animal Care and Use Committee.

Surgical Procedures

Fourteen conditioned male mongrel dogs weighing 28 ± 1 kg were premedicated with 10 mg intramuscular morphine sulfate and anesthetized with 20 mg/kg intravenous pentobarbital sodium and 15 μg/kg fentanyl citrate. An endotracheal tube was inserted, and the lungs were mechanically ventilated. Anesthesia was maintained with ~1.2% end-tidal

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
halothane. A left lateral thoracotomy was performed via the fifth intercostal space by using sterile surgical technique. The pericardium was incised ventral to the phrenic nerve. Heparin-filled Tygon catheters (1.02-mm ID; Norton, Akron, OH) were implanted in the descending thoracic aorta, main pulmonary artery, and left and right atria. The catheters were secured with purse-string sutures. A hydraulic occluder, and an electromagnetic flow probe (10-mm ID, Zepeda, Seattle, WA) was implanted around the left main pulmonary artery.

Seven dogs underwent LLA via sequential divisions and anastomoses of the left pulmonary veins, left mainstem bronchus, and left main pulmonary artery as previously described (26). The remaining seven dogs served as sham-operated controls. A wide circumferential pericardial incision mobilized the left lung. After 3,000 U heparin were administered intravenously, the left pulmonary veins (inferior, middle, and superior) were individually dissected to their point of confluence with the left atrium. These veins were then cross clamped, divided, and anastomosed with a continuous stitch of 7-0 Prolene suture. The left main pulmonary artery was isolated, crossed clamped, divided, and anastomosed with a continuous stitch of 6-0 Prolene suture. The left pulmonary artery cross-clamp time was ~15 min. Care was taken to avoid air emboli and luminal narrowing and to ensure good intimal apposition at the anastomotic sites. The pericardial edges were loosely apposed, and the free ends of the catheters, hydraulic occluder, and flow probe were threaded through the chest wall and tunneled subcutaneously to a final position between the scapulae. A chest tube was placed in the left thorax before closure and was removed on the first postoperative day. Intramuscular morphine sulfate (10 mg) was administered postoperatively for pain, as required. Intravenous ampicillin (1 g), cephalizin (1 g), and gentamicin (80 mg) were administered intraoperatively and for 10 days postoperatively.

Experimental Measurements

Vascular pressures were measured by attaching the fluid-filled catheters to strain-gauge manometers (model P23 ID, Gould Statham, Eastlake, OH) and were referenced to atmospheric pressure with the transducers positioned at midchest at the level of the spine. Heart rate was calculated from the phasic aortic pressure trace. Left pulmonary blood flow (LQ) was measured by connecting the flow probe to an electromagnetic flowmeter (model SWF-5RD, Zepeda). The flow probe was calibrated in vivo on a weekly basis by using the thermal-dilution technique. A 7-Fr balloon-tipped catheter was inserted percutaneously through an external jugular vein after topical lidocaine anesthesia and was positioned 2–3 cm beyond the pulmonic valve. The right pulmonary artery occluder was then inflated to direct total pulmonary blood flow through the left pulmonary artery (and flow probe). LQ was then measured by thermal dilution (HEMOPRO2, Spectramed, Oxnard, CA) with multiple, 10-ml sterile injectants of 5% dextrose in water. Values for LQ were referenced to body weight (ml·min⁻¹·kg⁻¹). Systemic arterial and mixed venous blood gases (pH, PO₂, PCO₂) were measured with a RadiometerABL-600 (Copenhagen, Denmark). Oxygenhemoglobin saturation (SO₂) was measured with a Radiometer Hemoximeter model OSM-3.

Experimental Protocols

All experiments were performed with each healthy unseeded conscious dog lying on its right side in a quiet laboratory environment. The seven LLA dogs were studied 30 ± 3 days after surgery. The seven sham-operated controls were studied 37 ± 3 days after surgery. Continuous LP-Q plots were used to assess the pulmonary vascular effects of hypoxia and the ET antagonists. LP-Q plots were constructed by continuously measuring the pulmonary vascular pressure gradient [pulmonary arterial pressure (PAP) – left atrial pressure (LAP)] and LQ during gradual (~1 min) inflation of the hydraulic occluder implanted around the right pulmonary artery. LP-Q plots are highly reproducible and have no effect on systemic hemodynamics, blood gases, or the zonal condition of the lung (21). Each dog was studied on 3 separate days in the intact condition, after selective ETA-receptor block, and after combined ETA-B-receptor block. The experiments were performed in random order with regard to group and ET antagonists. Because of technical failure (flow probes defective), LP-Q plots were obtained in six dogs in each group.

Protocol 1: Effect of LLA on the magnitude of hypoxic pulmonary vasoconstriction. We tested the hypothesis that LLA would result in an increase in the magnitude of HPV compared with normal conscious dogs. A baseline LP-Q plot was obtained during normoxia in the conscious state in six control dogs and six LLA dogs. A conical face mask was then placed over each dog’s snout. Room air was administered via the mask by using a semiclosed circulation system. After 15 min, a normoxia LP-Q plot with face mask was obtained. The delivered room air was then blended with gases from sources consisting of 100% nitrogen, oxygen, or carbon dioxide. The gas flows were titrated to the fraction of inspired oxygen tension (~11.2) that resulted in a gradual decrease in systemic arterial PO₂ to ~50 Torr. After a new steady state was reached (~30 min), a hypoxic LP-Q plot was generated.

Protocol 2: Effect of selective ETA-receptor block on the LP-Q relationship during normoxia and hypoxia. On a separate day, the procedures utilized in protocol 1 were repeated in the same dogs after pretreatment with the selective ETA-receptor antagonist BQ-485 (perhydroazeptin-1-yl-l-leucyl-D-tryptophanyl-d-tryptophan: 10 µg·kg⁻¹·min⁻¹ intravenous; a gift from Banyu Pharmaceuticals, Tsukuba, Japan). The efficacy of ETA-receptor block was demonstrated by the complete inhibition of the systemic pressor response to intravenous ET-1 (400 ng/kg). LP-Q plots were generated during normoxia, during normoxia after BQ-485, and during hypoxia. We tested the hypotheses that ETA-receptor inhibition would cause a downward shift in the baseline LP-Q relationship in LLA dogs and that ETA-receptor block would attenuate the magnitude of HPV in both control and LLA dogs.

Protocol 3: Effect of combined ETA-B-receptor block on the LP-Q relationship during normoxia and hypoxia. On a separate day, the procedures utilized in protocol 1 were repeated in the same dogs after pretreatment with the combined ETA-B-receptor antagonist bosentan (Ro 47–0203; 4-tert-butyl-5-(2-methoxy-phenoxy)-2,2’-bipyrimidin-4-yl]-benzene sulfonamide: 10 mg/kg bolus plus 100 mg·kg⁻¹·h⁻¹ intravenous infusion; a gift from Hoffmann-LaRoche, Basel, Switzerland). The efficacy of ETA-B-receptor block was demonstrated by the complete inhibition of the systemic pressor response to intravenous ET-1 (400 ng/kg). LP-Q plots were generated during normoxia, during normoxia after bosentan, and during hypoxia. We tested the hypotheses that combined ETA-B-receptor inhibition would inhibit the magnitude of HPV to a greater extent than would
ET<sub>A</sub>-receptor inhibition alone and that this effect would be more pronounced in LLA dogs.

**Measurement of Plasma ET-1 Concentration**

Blood samples were simultaneously collected from the main pulmonary artery and the left atrium to measure plasma ET-1 concentration during normoxia and after 30 min of hypoxia in seven control and seven post-LLA dogs. The blood samples were placed in chilled tubes containing protease inhibitors. After centrifugation, the plasma was stored at −20°C. After extraction through pretreated Sep-Pak C<sub>18</sub> columns (Waters Associates, Milford, MA), ET-1 concentration was measured in triplicate by radiommmunooassay (Peninsula Laboratories, Belmont, CA).

**Data Analysis**

Phasic and mean vascular pressures and LQ were displayed continuously on an eight-channel strip-chart recorder (model 2800, Gould, Eastlake, OH). Mean values for pressures and LQ, measured at end expiration, were obtained with passive electronic filters with a 2-s time constant. All vascular pressures were referenced to atmospheric pressure before and after each LP-Q˙ plot. The analog pressure and LQ signals were digitally converted and multiplexed (model PCM-8, Medical Systems, Greenvale, NY) and stored on videotape (videocassette recorder model AG-1260, Panasonic, Secaucus, NJ) for later playback and analysis. The LP-Q˙ relationship was measured continuously over the empirically measured range of LQ in each individual experiment. In all protocols, the LP-Q˙ relationship was linear by inspection over the empirically measured range of LQ. Thus linear regression analysis was used to calculate the slope and intercept for PAP − LAP (or PAP − 0 if LAP ≤ 0 mmHg) as a function of LQ in each individual experiment. The correlation coefficient for the LP-Q˙ relationship for each protocol averaged ≥ 0.98. The composite LP-Q˙ plots in Figs. 1, 2, 4, and 6 were generated by using the regression parameters from each individual continuously measured LP-Q˙ plot to calculate PAP − LAP at 10 ml·min<sup>-1</sup>·kg<sup>-1</sup> intervals of LQ over the empirically measured range of LQ. The minimum and maximum values of LQ in each composite LP-Q˙ plot represent the average minimum and maximum values of LQ for the dogs studied in that protocol. Multivariate analysis of variance in the form of Hotelling's T<sup>2</sup> was used to assess the effects of mask, hypoxia, BQ-485, bosentan, and LLA on the regression parameters obtained in each individual experiment, compared with values measured at baseline (50). One-way and two-way analyses of variance were used to assess the effects of interventions on steady-state hemodynamics and blood gases. Student's t-test for intragroup and intergroup comparisons was used to compare the effects of BQ-485 and bosentan on the magnitude of the HPV response and to assess changes in plasma ET-1 concentration between normoxia and hypoxia. All values are presented as means ± SE.

**RESULTS**

**Effect of LLA on the Magnitude of HPV**

As we have previously reported (26), LLA resulted in a marked leftward shift in the baseline LP-Q˙ relationship compared with conscious sham-operated, control dogs; i.e., LLA resulted in a chronic increase in pulmo-
LPA dogs. The HPV response (i.e., the increase in PAP – LAP, from normoxia to hypoxia at each common value of LQ) in control and LPA dogs is compared in Fig. 3. In both groups, the magnitude of HPV increased as LQ increased. Moreover, at any given value of LQ, the magnitude of HPV was increased post-LLA compared with control. Steady-state hemodynamics and blood gases are summarized in Tables 1 and 2, respectively. During normoxia, PAP was higher and LQ was lower post-LLA compared with control. Hypoxia increased PAP in both groups. Systemic arterial blood gases were similar in control and LPA dogs during normoxia. Hypoxia increased systemic arterial pH and decreased systemic arterial PCO2, PO2, and SO2, as well as mixed venous PO2 and SO2 to the same extent in both groups.

Effects of ET-Receptor Block in Control Dogs

The selective ETα-receptor antagonist BQ-485 had no effect on the LP-Q relationship during normoxia (Fig. 4A). After ETα-receptor block, breathing the hypoxic gas mixture still caused a leftward shift in the LP-Q relationship (Fig. 4A). However, the magnitude of the HPV response was attenuated after ETα-receptor block compared with the response measured in the intact condition (Fig. 5). Combined ETA-B-receptor block with bosentan had no effect on the LP-Q relationship during normoxia (Fig. 4B). Under these conditions, hypoxia still caused a shift in the LP-Q relationship (Fig. 4B). However, the magnitude of the HPV response was attenuated after combined ETA-B-receptor block com-

Table 1. Steady-state hemodynamics

<table>
<thead>
<tr>
<th></th>
<th>Protocol 1</th>
<th></th>
<th>Protocol 2</th>
<th></th>
<th>Protocol 3</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>LLA</td>
<td>Control</td>
<td>LLA</td>
<td>Control</td>
<td>LLA</td>
</tr>
<tr>
<td>SAP, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxia</td>
<td>89 ± 4</td>
<td>102 ± 3</td>
<td>89 ± 5</td>
<td>93 ± 3</td>
<td>84 ± 2</td>
<td>93 ± 3</td>
</tr>
<tr>
<td>ET antagonist</td>
<td>85 ± 3</td>
<td>93 ± 4</td>
<td>83 ± 2</td>
<td>93 ± 3</td>
<td>83 ± 3</td>
<td>87 ± 3</td>
</tr>
<tr>
<td>Mask</td>
<td>95 ± 7</td>
<td>97 ± 3</td>
<td>91 ± 3</td>
<td>99 ± 2</td>
<td>84 ± 2</td>
<td>92 ± 7</td>
</tr>
<tr>
<td>Hyopxia</td>
<td>98 ± 5</td>
<td>103 ± 6</td>
<td>113 ± 7</td>
<td>115 ± 12</td>
<td>119 ± 7</td>
<td>112 ± 12</td>
</tr>
<tr>
<td>PAP, mmHg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxia</td>
<td>17 ± 1</td>
<td>21 ± 1†</td>
<td>17 ± 1</td>
<td>21 ± 1†</td>
<td>17 ± 1</td>
<td>20 ± 1†</td>
</tr>
<tr>
<td>ET antagonist</td>
<td>17 ± 1</td>
<td>21 ± 1†</td>
<td>17 ± 1</td>
<td>21 ± 1†</td>
<td>16 ± 1</td>
<td>21 ± 2†</td>
</tr>
<tr>
<td>Mask</td>
<td>17 ± 1</td>
<td>21 ± 1†</td>
<td>17 ± 1</td>
<td>21 ± 2†</td>
<td>18 ± 1</td>
<td>21 ± 2†</td>
</tr>
<tr>
<td>Hyopxia</td>
<td>24 ± 1*</td>
<td>29 ± 1*†</td>
<td>24 ± 1*</td>
<td>29 ± 2*</td>
<td>23 ± 1*</td>
<td>25 ± 3*</td>
</tr>
<tr>
<td>LQ, ml·min⁻¹·kg⁻¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxia</td>
<td>67 ± 4</td>
<td>55 ± 3†</td>
<td>66 ± 4</td>
<td>58 ± 4</td>
<td>63 ± 2</td>
<td>53 ± 4†</td>
</tr>
<tr>
<td>ET antagonist</td>
<td>70 ± 4</td>
<td>58 ± 6</td>
<td>68 ± 4</td>
<td>62 ± 6</td>
<td>62 ± 5</td>
<td>63 ± 7</td>
</tr>
<tr>
<td>Mask</td>
<td>70 ± 9</td>
<td>52 ± 2</td>
<td>60 ± 5</td>
<td>52 ± 8</td>
<td>62 ± 5</td>
<td>63 ± 7</td>
</tr>
<tr>
<td>Hyopxia</td>
<td>59 ± 8</td>
<td>51 ± 4</td>
<td>66 ± 4</td>
<td>54 ± 7</td>
<td>69 ± 5</td>
<td>63 ± 7</td>
</tr>
<tr>
<td>HR, beats/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxia</td>
<td>98 ± 10</td>
<td>111 ± 9</td>
<td>101 ± 8</td>
<td>118 ± 10</td>
<td>100 ± 7</td>
<td>107 ± 13</td>
</tr>
<tr>
<td>ET antagonist</td>
<td>113 ± 7</td>
<td>115 ± 12</td>
<td>119 ± 7</td>
<td>112 ± 12</td>
<td>124 ± 14</td>
<td>124 ± 14</td>
</tr>
<tr>
<td>Mask</td>
<td>103 ± 14</td>
<td>96 ± 5</td>
<td>111 ± 15</td>
<td>106 ± 13</td>
<td>102 ± 11</td>
<td>124 ± 14</td>
</tr>
</tbody>
</table>

Values are means ± SE. SAP, systemic arterial pressure; PAP, pulmonary arterial pressure; LAP, left atrial pressure; LQ, left pulmonary blood flow; HR, heart rate; ET, endothelin antagonist: BQ-485 in protocol 2, bosentan in protocol 3; LLA, left lung autotransplantation. Protocol 1: effect of LLA on the magnitude of hypoxic pulmonary vasoconstriction. Protocol 2: effect of selective ETα-receptor block. Protocol 3: effect of combined ETA-B-receptor block. *P < 0.05, hypoxia vs. normoxia. †P < 0.05, LLA vs. control.
pared with the intact condition (Fig. 5). The magnitude of HPV was attenuated to a greater extent during combined ETA,-receptor block compared with selective ETA,-receptor block (Fig. 5). Neither BQ-485 nor bosentan had effects on steady-state hemodynamics or blood gases (Tables 1 and 2).

Effects of ET Receptor Block in Post-LLA Dogs

Neither selective ETA,-receptor block (Fig. 6A) nor combined ETA,-+B-receptor block (Fig. 6B) had an effect on the LP-Q relationship during normoxia. Under these conditions, hypoxia still caused a shift in the LP-Q relationship (Fig. 6). The magnitude of HPV was attenuated by selective ETA,-receptor block and was reduced to an even greater extent by combined ETA,-+B-receptor block (Fig. 7). BQ-485 decreased the HPV response to a similar extent in control and post-LLA dogs, whereas bosentan attenuated the HPV response to a greater extent in the LLA group (Fig. 8). Neither ET-receptor antagonist had an effect on steady-state hemodynamics or blood gases (Tables 1 and 2).

Plasma ET-1 Concentrations During Normoxia and Hypoxia in Control and LLA Dogs

Pulmonary arterial and left atrial plasma ET-1 concentrations were similar during normoxia in control and LLA dogs (Fig. 9). Hypoxia induced a small increase in the left atrial plasma ET-1 concentration in LLA dogs but not in control dogs (Fig. 9).

**DISCUSSION**

The overall goal of this study was to investigate the role of endogenous ET in regulation of the pulmonary circulation after LLA. Our main findings are the following: 1) ET does not mediate the chronic increase in pulmonary vascular resistance post-LLA, 2) the magnitude of HPV is enhanced post-LLA, 3) both ETA,- and ETB,-receptor activation are involved in the HPV response in control and LLA dogs, and 4) the vasoconstrictor role of ETB,-receptor activation during HPV is potentiated post-LLA.

As our laboratory has previously reported (26, 29-31), LLA resulted in a chronic increase in pulmonary vascular resistance. Sympathetic alpha,-adrenoreceptor activation mediates a portion of this effect, because inhibition of alpha,-adrenoreceptors partially reverses the shift in the LP-Q relationship post-LLA (29). Angiotensin II-receptor activation also mediates a component of the increase in pulmonary vascular resistance post-LLA (9). We postulated that endogenous ET may also be involved in the chronic increase in pulmonary vascular resistance post-LLA.

### Table 2. Steady-state blood gases

<table>
<thead>
<tr>
<th></th>
<th>Protocol 1</th>
<th>Protocol 2</th>
<th>Protocol 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>LLA</td>
<td>Control</td>
</tr>
<tr>
<td><strong>Systemic arterial</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH  Normoxia</td>
<td>7.38±0.01</td>
<td>7.40±0.01</td>
<td>7.38±0.01</td>
</tr>
<tr>
<td>ET antagonist</td>
<td>7.41±0.02*</td>
<td>7.45±0.01*</td>
<td>7.44±0.01*</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>40±1</td>
<td>39±1</td>
<td>41±1</td>
</tr>
<tr>
<td><strong>PCO₂, Torr</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxia</td>
<td>35±1*</td>
<td>35±1*</td>
<td>33±1*</td>
</tr>
<tr>
<td>ET antagonist</td>
<td>97±3</td>
<td>92±2</td>
<td>92±1</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>97±1</td>
<td>97±1</td>
<td>97±1</td>
</tr>
<tr>
<td><strong>SO₂, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normoxia</td>
<td>79±1*</td>
<td>82±1*</td>
<td>82±1*</td>
</tr>
</tbody>
</table>

Values are means ± SE. So₂, oxyhemoglobin saturation. *P < 0.05, hypoxia vs. normoxia. †P < 0.05, LLA vs. control.
resistance post-LLA. The rationale for this hypothesis is that ET has been implicated in experimental (5, 15, 24, 47) and human (2, 3, 8) pulmonary hypertension. Moreover, LLA is characterized by profound abnormalities in endothelial function (11, 37, 54). However, neither of the ET antagonists had an effect on the baseline LP-Q˙ relationship during normoxia. Thus endogenous ET does not mediate the active increase in pulmonary vascular resistance post-LLA. However, our experimental design does not rule out the possibility that ET may exert chronic effects on the pulmonary circulation (e.g., structural changes) post-LLA.

The vascular actions of ET are mediated by at least two receptor subtypes, ET_A and ET_B receptors. Classically, it was thought that activation of ET_A receptors on vascular smooth muscle caused vasoconstriction, whereas activation of ET_B receptors on endothelial cells caused vasodilation via the release of endothelium-derived relaxing factors. However, recent evidence suggests that ET_B-receptor activation can also result in vasoconstriction in human blood vessels (39), including pulmonary artery (21). At present it is uncertain whether different subtypes of ET_B receptors are present on endothelial and vascular smooth muscle cells (7). One possible limitation of our study is that we did not utilize a selective ET_B-receptor antagonist. We assumed that differences between the effects of BQ-485 and bosentan are due to the net effect of inhibiting ET_B receptors.
HPV is a compensatory mechanism whereby a decrease in alveolar $P_{O_2}$ results in constriction of adjacent pulmonary arterioles, which improves gas exchange by diverting pulmonary blood flow away from hypoxic regions to better ventilated regions of the lung. The mechanism responsible for HPV is intrinsic to the lung, because HPV has been demonstrated on numerous occasions in isolated lung preparations. There are conflicting reports in the literature concerning the role of ET in the HPV response. Evidence to support a role for ET has been reported in rats (5, 6, 15, 33), lambs (48), pigs (12, 16, 17), and dogs (51). Conversely, ET was not found to play a role in the HPV response in rats (13, 45), lambs (52), and dogs (10). Possible confounding factors that could be responsible for these conflicting results include the use of anesthetics, acute surgical trauma, artificial perfusion, and single-point calculations of pulmonary vascular resistance. Our experimental model avoids these confounding factors. Our results suggest that both ETA- and ETB-receptor activation mediate components of the HPV response. Both ET antagonists attenuated the HPV response. Moreover, the effects of combined ETA-B-receptor block were greater than those of selective ETA-receptor block.

The LLA procedure results in surgical denervation of the lung. We did not anticipate that denervation per se would alter the HPV response post-LLA, because we have previously demonstrated that the autonomic nervous system does not mediate or modulate the HPV response in conscious dogs (20). It is known in a qualitative sense that the HPV response persists in the human transplanted lung (23, 35). We observed that the HPV response was potentiated post-LLA. Although the precise mechanism that mediates HPV remains to be elucidated, it is well established that several endogenous vasodilator mechanisms (e.g., nitric oxide, prostacyclin, ATP-sensitive K channel activation) act to modulate the HPV response (18, 19, 27). Pulmonary vasodilation mediated by nitric oxide (37) and ATP-sensitive K channel activation (38) are attenuated post-LLA. Thus the potentiated HPV response post-LLA could be due to a reduction in the influence of these vasodilator pathways. In addition, in the present study we observed that the inhibitory effect of ETA-receptor block was similar in control and LLA dogs, whereas the...

Fig. 7. HPV response in post-LLA dogs in intact condition, after ETA-receptor block with BQ-485, and after ETB-receptor block with bosentan. Magnitude of HPV was attenuated ($^*P<0.01$) by BQ-485 and was reduced further ($^{\dagger}P<0.01$) by bosentan. Values are means ± SE.

Fig. 8. Percent attenuation in HPV response induced by selective ETA- or combined ETA-B-receptor block at left pulmonary blood flow = 80 ml·min$^{-1}$·kg$^{-1}$ in control and post-LLA dogs. In both groups, magnitude of HPV was attenuated ($^*P<0.05$) to a greater extent by bosentan compared with BQ-485. Attenuation in HPV response induced by BQ-485 was similar in control and post-LLA dogs, whereas bosentan exerted a greater effect in post-LLA dogs compared with control ($^{\dagger}P<0.05$). Values are means ± SE.

Fig. 9. Plasma ET-1 concentration in left atrium (A) and pulmonary artery (B). Blood samples were taken during normoxia and hypoxia in 7 control and 7 LLA dogs. Plasma ET-1 concentration in the pulmonary artery did not change during hypoxia in either group. Plasma ET-1 concentration in the left atrium only increased ($^*P<0.05$) during hypoxia in post-LLA dogs. Values are means ± SE.
effect of combined ET<sub>A</sub><sup>B</sup>-receptor block was greater post-LLA compared with control. One possible explanation for these results is a shift in the relative contribution of endothelial and vascular smooth muscle ET<sub>B</sub> receptors post-LLA. For example, if the vasoconstrictor influence of endothelial ET<sub>B</sub>-receptor activation is diminished post-LLA, this would result in a potentiated HPV response mediated by vascular smooth muscle ET<sub>B</sub>-receptor activation.

There is a relative paucity of information concerning the role of ET in the setting of lung transplantation. Combined ET<sub>A</sub><sup>B</sup>-receptor block has been shown to ameliorate ischemia-reperfusion injury in canine lung allografts (40). Plasma ET concentrations are elevated after experimental (40, 41) and human (42) lung transplantation, although values return to baseline concentrations within 1 wk of the transplantation procedure. ET is also increased in the bronchoalveolar lavage fluid of patients with lung allografts (1, 36). It has been postulated that ET may be involved in chronic rejection and the development of obliteratorive bronchiolitis (22, 34, 44). We did not observe an increase in plasma ET concentration during normoxia after LLA, perhaps because measurements were made 1 mo after the LLA procedure. More surprisingly, we did not observe an increase in plasma ET in response to hypoxia in the control group and only observed a small increase in the LLA group. This result appears to be inconsistent with the marked effects of the ET antagonists on the HPV response. We can only speculate that plasma concentrations of ET do not accurately reflect the local tissue concentration.

It is important to note that the magnitude of HPV was directly proportional to the level of pulmonary blood flow in both control and post-LLA dogs (Figs. 3, 5, and 7). The flow-dependent nature of HPV must be taken into account when investigating the effects of physiological or pharmacological interventions on the HPV response. This factor may account for some of the conflicting reports in the literature concerning the role of ET in the HPV response.

In summary, ET does not mediate the chronic increase in pulmonary vascular resistance post-LLA. Both ET<sub>A</sub>- and ET<sub>B</sub>-receptor activation mediate components of the HPV response. The vasoconstrictor role of ET<sub>B</sub>-receptor activation during HPV appears to be potentiated post-LLA.

The authors gratefully acknowledge the technical support of Steve Schomisch, Pantelis Konstantinopoulos, and Mike Trenantelli. The authors also thank Cassandra Talercio for outstanding work in preparing the manuscript. They also thank Banyu Pharmaceuticals and Hoffmann-La Roche for their kind gifts of BQ-485 and bosentan, respectively. This study was supported by National Heart, Lung, and Blood Institute Grants HL-40361 and HL-38291. S. Doi was also supported by Dr. J un-ichi Yata (Dept. of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan).

Address for reprint requests and other correspondence: P. A. Murray, Center for Anesthesiology Research, FF 40, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195 (E-mail: murrayp@ccf.org).

Received 16 February 1999; accepted in final form 14 September 1999.

REFERENCES


Received from http://jap.physiology.org/ by 10.220.32.247 on October 15, 2017


